港股異動 | 亞盛醫藥-B(6855.HK)高開近15% 原創1類新藥奧雷巴替尼有治療新冠潛力
格隆匯5月19日丨亞盛醫藥-B(6855.HK)高開14.9%,報15.42港元,總市值40億港元。該公司昨日公吿,一項由位於西雅圖Fred Hutchinson癌症研究中心的研究人員開展的最新臨牀前研究發現,奧雷巴替尼(耐立克)對於新冠病毒變異毒株奧密克戎(SARS-CoV-2-Omicron)誘導的細胞因子風暴具有治療潛力。該研究成果已於今日在國際着名期刊《EMBO分子醫學》(EMBO Molecular Medicine)上發表。奧雷巴替尼已在中國獲批上市,用於治療任何TKI耐藥,並伴有T315I突變的慢性期(CP)或加速期(AP)慢性髓細胞白血病(CML)。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.